![]() ![]() Cash, cash equivalents and marketable equity securities of $15.6 million and working capital of $42.8 million as of March 31, 2023.Adjusted EBITDA of $3.1 million for the three months ended March 31, 2023, as compared to adjusted EBITDA of $14.6 million for the three months ended March 31, 2022.Net Income of $0.6 million, or $0.03 per diluted share, for the three months ended March 31, 2023, as compared to net income of $12.5 million, or $0.68 per diluted share, for the three months ended March 31, 2022.Net revenue of $19.3 million for the three months ended March 31, 2023, as compared to $47.5 million for the three months ended March 31, 2022.Implemented new $6 million stock repurchase program.įinancial highlights for the three months ended March 31, 2023, include the following:.Growing Pharmaloz Manufacturing with almost 100% year-over-year growth.Growing Nebula Genomics with over 100% revenue growth year-over-year.Continuing sample acquisition and testing of BE-Smart Test at the cutting-edge facility at Mprobe.Developing the BE-Smart Esophageal Cancer Test with world-renowned Key Opinion Leaders at Mayo Institute, Kansas University Medical Center (KUMC) and Baylor University.Conducting vital pre-clinical analysis of Linebacker-1 at Eurofins and Reprocell.Advancing key initiatives associated with Linebacker-1 cancer compound at the world-renowned Dana Farber Cancer Institute with Harvard University professors/scientists.(NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2023.Ĭorporate highlights for the three months ended March 31, 2023, include the following: Garden City, NY, (GLOBE NEWSWIRE) - ProPhase Labs, Inc. Notes payable of $20,000 were issued for $20,000 cash.As revenue mix transitions, Company still achieves positive net income and significant adjusted EBITDA while acquiring and developing biotech, genomics and diagnostic assets with multi-billion-dollar potentialĬompany highlights key strategic initiatives to grow underlying value in 2023 and beyondĬompany to hold a conference call T hursday, May 11, 202 3, at 11:00 AM ET.The company purchased plant assets for $70,000 cash. ![]() Scoreteck’s only noncash expense was $70,000 of depreciation.Dividends of $80,000 cash were declared and paid. ![]() Identify the debits and credits in the Analysis of Changes columns with letters that correspond to the following transactions and events a through h. (The statement of cash flows is not required.) Prepare the spreadsheet as in Exhibit 12A.1 report operating activities under the indirect method. Plus, the net increase in the equipment account balanceĬomplete the following spreadsheet in preparation of the statement of cash flows. Net cash provided by operating activitiesĬalculation of Cash received from the sale of equipmentĪccumulated depreciation of equipment sold Income statement items not affecting cashĬhanges in current operating assets and liabilities Statement of Cash Flows (Indirect Method)Īdjustment to reconcile net income to net cash provided by operating activities
0 Comments
Leave a Reply. |